THE ANALYSIS OF INFLUENCE OF CLINICAL PREDICTORS ON THE RESULTS OF TREATMENT WITH ERLOTINIB IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)

被引：0
|
作者：
Salajka, Frantisek [1 ]
Pesek, Milos [2 ]
Krejci, Jana [3 ]
Skrickova, Jana [4 ]
Zatloukal, Petr
Koubkova, Leona
Grygarkova, Ivona
Hrnciarik, Michal [1 ]
Sticha, Michal [5 ]
机构：
[1] Univ Hosp, Dept Pneumol, Bulovka, Czech Republic
[2] Univ Hosp Plzen, Dept Pneumol, Plzen, Czech Republic
[3] Charles Univ Hosp Plzen, Dept Pneumol, Plzen, Czech Republic
[4] Univ Hosp Brno, Dept Resp Dis & Tb, Brno, Czech Republic
[5] Masaryk Univ, CS-60177 Brno, Czech Republic
来源：
JOURNAL OF THORACIC ONCOLOGY | 2011年 / 6卷 / 06期
关键词：
NSCLC; erlotinib; clinical predictors;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S1293 / S1294
页数：2
相关论文
共 50 条
  • [31] Clinical Laboratory Results as Prognosis Marker in Advanced Stage Non-small Cell Lung Cancer (NSCLC) in Indonesia
    Hanafi, Arif R.
    Jayusman, Achmad M.
    Sutandyo, Noorwati
    Kurniawati, Sri
    Setiawan, Lyana
    Diandra, Alyssa
    Hidayat, Kusmantoro
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (09)
  • [32] Impacts of Treatment Lines and Initiation Timing of Erlotinib for Advanced Non-small Cell Lung Cancer
    Aoki, Takuya
    Igawa, Satoshi
    Furuya, Naoki
    Katagiri, Masato
    Hisata, Junichirou
    Tajiri, Sakurako
    Hayama, Naoki
    Mineshita, Masamichi
    Urano, Tetsuya
    Miyazawa, Teruomi
    Masuda, Noriyuki
    Abe, Tadashi
    ANTICANCER RESEARCH, 2012, 32 (02) : 601 - 608
  • [33] ERLOTINIB IN NON-SMALL CELL LUNG CANCER: ANALYSIS OF TOXICITY AND EFFICACY IN CLINICAL PRACTICE
    Alexandre, Maria Teresa A.
    Ip, Joana
    Duarte, Isabel
    Almodovar, Teresa
    Da Costa, Jose Duro
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1326 - S1327
  • [34] Gefitinib and Afatinib Treatment in an Advanced Non-small Cell Lung Cancer (NSCLC) Patient Undergoing Hemodialysis
    Bersanelli, Melissa
    Tiseo, Marcello
    Artioli, Fabrizio
    Lucchi, Leonardo
    Ardizzoni, Andrea
    ANTICANCER RESEARCH, 2014, 34 (06) : 3185 - 3188
  • [35] Reviewing the safety of erlotinib in non-small cell lung cancer
    Reck, Martin
    Mok, Tony
    Wolf, Juergen
    Heigener, David
    Wu, Yi-long
    EXPERT OPINION ON DRUG SAFETY, 2011, 10 (01) : 147 - 157
  • [36] Efficacy of erlotinib and celecoxib for patients with advanced non-small cell lung cancer: A retrospective study
    Jin, Yi-Hua
    Li, Wei-Hong
    Bai, Yan
    Ni, Lei
    MEDICINE, 2019, 98 (10)
  • [37] Phase II Study of Erlotinib in Japanese Patients with Advanced Non-small Cell Lung Cancer
    Takahashi, Toshiaki
    Yamamoto, Nobuyuki
    Nukiwa, Toshihiro
    Mori, Kiyoshi
    Tsuboi, Masahiro
    Horai, Takeshi
    Masuda, Noriyuki
    Eguchi, Kenji
    Mitsudomi, Tetsuya
    Yokota, Soichiro
    Segawa, Yoshihiko
    Ichinose, Yukito
    Fukuoka, Masahiro
    Saijo, Nagahiro
    ANTICANCER RESEARCH, 2010, 30 (02) : 557 - 563
  • [38] Clinical and Plasma Biomarkers for Disease Control with Nivolumab Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC)
    Daher, Sameh
    Lawrence, Yaacov
    Dudnik, Elizabeth
    Hanovich, Ekaterina
    Urban, Damien
    Peled, Nir
    Navon, Rossie
    Leibowitz-Amit, Raya
    Hammerman, Ariel
    Battat, Erez
    Bar, Jair
    Onn, Amir
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1307 - S1307
  • [39] A COMPARATIVE CLINICAL AND COST-EFFECTIVENESS EVALUATION OF GEFITINIB AND ERLOTINIB IN THE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER
    Lopes, Gilberto D. L., Jr.
    Segel, Joel
    Tan, Daniel
    Do, Young
    Mok, Tony
    Finkelstein, Eric
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1306 - S1307
  • [40] Erlotinib for the treatment of brain metastases in non-small cell lung cancer
    Brower, Jeffrey V.
    Robins, H. Ian
    EXPERT OPINION ON PHARMACOTHERAPY, 2016, 17 (07) : 1013 - 1021
12345